🔗 Share this article

While America undertakes historic revisions to its vaccine recommendations, one figure appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by questioning coronavirus shots in the pandemic and has zeroed in on potential deaths after Covid vaccination in her short position at the FDA.

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities were set to reveal radical revisions to the childhood vaccination calendar in December, aligning the US with the Danish vaccine program, it is understood – a significant shift that would place the US at odds with a large portion of the global community with no evidence for benefit. The announcement has been delayed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is listed to address the audience at the meeting. She was recently named acting director of the FDA’s CDER, the fifth appointee to run the division this calendar year.

A Shift at the Agency

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon dismantling long-standing immunizations at the FDA.

Høeg has frequently advocated for discontinuing specific childhood vaccine recommendations in the US so as to align more like Denmark, a society with universal health coverage and a citizenry approximately the population of Wisconsin’s.

So far statements, she has persisted in emphasizing on immunizations – usually the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Questions Over Background

Dr. Høeg has no apparent experience in drug development, approval processes or management, which has been typical for previous heads of the CBER. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in leading a major agency. She lacks background in industry regulation.”

Previous directors of CBER would “be deeply familiar with legal statutes and the research of drug development”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that prior appointees who ran the center have had.”

This division has an enormous portfolio at the agency, the former commissioner pointed out.

“The public just pays attention on the new drug program, but the generic drug division authorizes a multitude of generic drugs. There’s a biosimilars division, non-prescription drug unit and more, and every single one have to be managed,” Dr. Woodcock said. “The responsibility you overlook, that is the part that I always told people is going to bite you.”

There is also, a major administrative component to the position, which supervises in excess of 5,000 personnel. “It is a huge management job, if you execute it properly,” the former official concluded.

Official Statement and Controversial Programs

In response to inquiries about Dr. Høeg's qualifications and whether this appointment indicates greater collaboration among regulatory chiefs on immunizations, a press secretary responded that the “questions rely on inaccurate presumptions”.

“Her experience is consistent with the functions of her job,” the spokesperson said, noting the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg inherits the agency head's recently launched expedited review system, a contentious one-day drug-approval program that allegedly concerned her former heads. “How are these medications being selected for this fast-track system? Who takes the calls?” Dr. Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards more relaxed oversight of all drugs, aside from immunizations.”

Public Past Work on Vaccines

With immunizations, Høeg has a more documented, if troubling, history, Howard have noted. She authored a study using unconfirmed volunteer-provided data to estimate the frequency of myocarditis after COVID-19 immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the incoming federal leadership featured revising rules for recently developed shots and ending “unnecessary” immunizations, she remarked post-election on a podcast. At the agency, Høeg has according to sources proposed barring adolescent males from obtaining Covid vaccines.

“She is an thorough dogmatist who starts off with her preconceived notions and reverse-engineers to fit the science in a extremely disingenuous, dishonest way,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined other dissenters, {like|